Greenphire Expands Global Travel Solution, ConneX
Greenphire has announced the expansion and growth of ConneX, a clinical trial travel solution designed to help meet the retention goals of global studies.
ConneX has expanded upon its in-market resources in key regions, including Japan, Central and Southern Europe, Scandinavia, and Southeast Asia.
In support of global trial retention, ConneX offers a host of personalized concierge services, including air, train, hotel, car services and rideshare, ambulatory care, and specialty services. This includes travel visa support, with successful applications recently processed for patients traveling from Jordan to Germany and Iraq to the USA.
Reference
Greenphire's ConneX Global Travel Solution Expands In-Country Support, Resulting in Significant Growth as Clinical Trial Travel Returns Post-Pandemic. (2023, February 28). Cision PR Newswire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
